ArticleEvidence-based complementary and alternative medicine : eCAM2013
Effect of GutGard in the Management of Helicobacter pylori: A Randomized Double Blind Placebo Controlled Study.
Article in Evidence-based complementary and alternative medicine : eCAM, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Effect of polyphenol compounds onBMJ open · 2023Pooled it
- Vegetable Extracts and Nutrients Useful in the Recovery fromMolecules (Basel, Switzerland) · 2021Pooled it
- Medicinal plants--prophylactic and therapeutic options for gastrointestinal and respiratory diseases in calves and piglets? A systematic review.BMC veterinary research · 2016Pooled it
- Trial
- To evaluate of the effect of adding licorice to the standard treatment regimen of Helicobacter pylori.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesTrial
- Beyond Antibiotics: Alternative Strategies TargetingExpert reviews in molecular medicine · 2026Review
- Real-World Evidence on Different Amoxicillin-Containing Regimens forAntibiotics (Basel, Switzerland) · 2026Article
- Medicinal Plants in Food Supplements for Gastrointestinal Disorders: Critical Assessment of Health Claims on Gastric Acid Regulation.Nutrients · 2025Review
- Natural foods resources and dietary ingredients for the amelioration ofFrontiers in medicine · 2023Review
- A flavonoid rich standardized extract of Glycyrrhiza glabra protects intestinal epithelial barrier function and regulates the tight-junction proteins expression.BMC complementary medicine and therapies · 2022Article
- Acute and Subchronic Toxicity Study of Flavonoid Rich Extract ofJournal of toxicology · 2022Article
- Phytochemicals: A Promising Weapon in the Arsenal against Antibiotic-Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2021Review
- Anti-Laboratory animal research · 2020Article
- In Silico and In Vitro Anti-Molecules (Basel, Switzerland) · 2019Article
- Overview of the phytomedicine approaches against Helicobacter pylori.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A randomized, double blind placebo controlled study was conducted to evaluate the efficacy of GutGard (root extract of Glycyrrhiza glabra) in the management of Helicobacter pylori (H. pylori) gastric load. Participants diagnosed with H. pylori infection were randomly assigned to two groups to orally receive 150 mg of GutGard (n = 55) or placebo (n = 52) once daily for 60 days. H. pylori infection was assessed using (13)C-urea breath test ((13)C-UBT) at days 0, 30, and 60. Stool Antigen test (HpSA) was also performed on days 0, 30, and 60. Repeated measures of analysis of variance (RMANOVA), chi-square, and Fisher's exact probability tests were used to compare the treatment outcomes. A significant interaction effect between group and time (P = 0.00) and significant difference in mean Delta Over Baseline (DOB) values between GutGard (n = 50) and placebo (n = 50) treated groups after intervention period were observed. On day 60, the results of HpSA test were negative in 28 subjects (56%) in GutGard treated group whereas in placebo treated group only 2 subjects (4%) showed negative response; the difference between the groups was statistically significant. On day 60, the results of (13)C-UBT were negative in 24 (48%) in GutGard treated group and the difference between the groups was statistically significant. The findings suggest GutGard is effective in the management of H. pylori.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.